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Abstract
Undetected errors in the expression measurements from high-
throughput DNA microarrays and protein spectroscopy could 
seriously affect the diagnostic reliability in disease detection. 
In addition to a high resilience against such errors, diagnos-
tic models need to be more comprehensible so that a deeper 
understanding of the causal interactions among biological en-
tities like genes and proteins may be possible. In this paper, 
we introduce a robust knowledge discovery approach that ad-
dresses these challenges. First, the causal interactions among 
the genes and proteins in the noisy expression data are discov-
ered automatically through Bayesian network learning. Then, 
the diagnosis of a disease based on the network is performed 
using a novel error-handling procedure, which automatically 
identiﬁes the noisy measurements and accounts for their un-
certainties during diagnosis. An application to the problem of 
ovarian cancer detection shows that the approach effectively 
discovers causal interactions among cancer-speciﬁc proteins. 
With the proposed error-handling procedure, the network per-
fectly distinguishes between the cancer and normal patients.
Introduction
In the year 2007, 22,430 American women are expected to 
be diagnosed with ovarian cancer, and 15,280 women could 
die from it (American Cancer Society 2007). As symptoms 
surface only in the advanced stages, the 5-year survival rate 
is just 45%. The chances of survival rise to 93% if the cancer 
is diagnosed early, but just 19% of cases are detected at early 
stages. There is hence a strong association between the high 
morbidity and the lack of a reliable early screening method. 
Based upon the hypothesis that disease-speciﬁc proteins, 
or proteomic biomarkers, might be secreted into the blood 
stream from pathological changes in affected organs, recent 
discovery of differentially expressed proteins in ovarian can-
cer patients looks promising. Using a surface enhanced laser 
desorption and ionization time-of-ﬂight (SELDI-TOF) mass 
spectroscopy to proﬁle the proteins in the patients’ sera, Pet-
ricoin et al. (2002) describe a technique that could identify 
ovarian cancer patients with perfect sensitivity (cancer-class 
recall) and a high speciﬁcity (normal-class recall) of 95%. 
Their approach has since been applied for the diagnosis of 
prostrate (Wellmann et al. 2002) and other types of cancers.
Indeed, being able to provide an almost perfect sensitivity
and speciﬁcity is a necessary requirement for cancer detec-
tion methods. As the prevalence of each cancer in the pop-
ulation is relatively low, a high predictive value is necessary
to minimize incorrect diagnoses. This has been the focus of
prior researches (e.g. Petricoin et al. 2002, Zhu et al. 2003).
However, being able to diagnose accurately on particular
data sets does not guarantee that a learned classiﬁer performs
well on the general population. In fact, it is found that classi-
ﬁers that are learned from different ovarian cancer data sets
differ greatly, such that each classiﬁer predicts accurately on
its own data set, but performs poorly on another (Baggerly,
Morris, & Coombes 2004). In addition to having high accu-
racy on representative samples, a model that describes bio-
logically plausible causal interactions among genes and pro-
teins is far more likely to be generalizable. Hence, a second
important requirement of a cancer detection method is that
it should be able to encode the causal feature interactions, in
a way that we can interpret, comprehend, and further verify.
There are a number of challenges in satisfying the two re-
quirements. Existing protein analysis techniques depend on
mass spectral data streams that are infested with substantial
electronic noise and chemical noise due to contaminants and
matrix effects (Petricoin et al. 2002). Likewise, the gene ex-
pression data from high-throughput methods like DNA mi-
croarrays are extremely noisy (Friedman et al. 2000). For
robust diagnoses, there is a need for an error-handling proce-
dure that reliably discovers the unknown error rates underly-
ing the observations and accounts for these when predicting.
To fulﬁl the second requirement of causal interpretability,
a thorough knowledge discovery method for disease diag-
nosis has to examine all the candidate features so as not to
overlook the handful of potential markers. In addition, there
is a need to reliably discover the causal interactions among
the features, so that the intrinsic mechanism of diagnosis can
become clear. Ideally, the method must be able to learn the
causal interactions from data without external information,
but it should also allow for leveraging of prior knowledge in
learning, as well as reﬁnement by experts after construction.
In this paper, we introduce a knowledge discovery ap-
proach that can address these challenges. After applying
a dimensionality reduction method, an automatic Bayesian
network learning algorithm discovers the underlying causal
interactions among features. The learned Bayesian network
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causal model captures these feature interactions in a graph
that can be readily inspected and reﬁned by human experts.
For robustness against noise, we introduce a novel procedure
that automatically identiﬁes the erroneous features and ac-
counts for their uncertainties during predictions. Although
we describe the proposed approach’s usefulness within the
noisy biological domain in this paper, the same approach can
be effectively applied to analyze any noisy data in general.
We evaluate the mechanism by applying it to ovarian can-
cer detection. By utilizing our proposed error-handling pro-
cedure, the network achieves a perfect speciﬁcity and sensi-
tivity on unseen data. At the same time, in contrast to the in-
comprehensible “black-box” nature of other prediction mod-
els, the learned network offers an interpretable model of the
causal interactions among the proteins related to the cancer.
The rest of this paper is organized as follows. We start off
by describing the ovarian cancer data set we have analyzed,
and the related literature and prior results. Next, we describe
the key phases of our knowledge discovery approach. Fol-
lowing that, we present the major evaluation results. Finally,
we conclude this paper with a discussion of future work.
The Ovarian Cancer Data Set
We analyze our proposed mechanism based on the raw mass
spectra data set that is publicly-available online at the web
site of the United States National Cancer Institute’s Center
for Cancer Research’s Clinical Proteomics Program Data-
bank (http://home.ccr.cancer.gov/ncifdaproteomics) (Ovar-
ian Data Set 8-7-02). The experiment aims to ﬁnd proteomic
patterns in blood serum that distinguish patients with ovar-
ian cancer from those without. This is especially important
for early detection in women who are at high risk of ovarian
cancer due to a family or personal history of cancer, and for
women with genetic predisposition to ovarian cancer due to
abnormal BRCA1 and BRCA2 genes (Liede & Narod 2002).
The data set comprises of 162 serum proﬁles from ovarian
cancer patients, and 91 proﬁles from normal subjects who do
not have cancer. The ovarian cancer patients consist of 28
stage I patients, 20 stage II patients, 99 stage III patients, 12
stage IV patients, and 3 patients who were at an unspeciﬁed
stage. The data set had been collected from blood samples of
the human subjects using the Ciphergen WCX2 ProteinChip
array. The samples were prepared with a robotic instrument,
and the raw data without any baseline subtraction was posted
for download. The proﬁle for the subjects comprises 15,154
distinct mass-to-charge ratios (M/Z values) of intensities that
range from 0.0000786 to 19995.513 (Sorace & Zhan 2003).
Related Work
Lilien, Farid, & Donald (2003) develop the Q5 algorithm for
classifying the SELDI-TOF serum spectra. They use Princi-
ple Component Analysis (Duda & Hart 1973) to reduce the
dimensionality before classifying using Linear Discriminant
Analysis (Fisher 1936). The method’s prediction conﬁdence
is deﬁned in a normal Gaussian distribution centered at each
of the class means, where a higher threshold allows for more
conﬁdence at the expense of fewer classiﬁable samples. For
the same ovarian data set, they report that a particular thresh-
old exists for which Q5 classiﬁes perfectly, but it is not clear
how this crucial threshold value could be determined in gen-
eral. More importantly, principle component analysis gener-
ates new features that cannot be related back to the proteins.
Sorace & Zhan (2003) have used the Wilcoxon nonpara-
metric test to ﬁnd M/Z values having the largest differences
between cancer and normal sera, and stepwise discriminant
analysis to develop rules for diagnosis. For this ovarian can-
cer data, they have presented two rules that can classify per-
fectly. However, their rules involve proteins withM/Z values
as low as only 2.792 and 2.823. As the authors and later Bag-
gerly, Morris, & Coombes (2004) have clearly highlighted,
this can be a major point of concern since it is very difﬁcult
to offer any biological explanation for the observed differ-
ence in such a low M/Z region. As they have not learned the
protein interactions, their method cannot be used to examine
these features’ relations to other proteins and ovarian cancer.
Li &Wong (2003) have compared the performance of two
rule-induction algorithms, the C4.5 (Quinlan 1993) and their
own PCL classiﬁer, based on this same set of ovarian cancer
data. They have reported that the decision tree that is learned
by C4.5 misclassiﬁes ten out of about 25 test samples, while
their PCL classiﬁer, which uses multiple signiﬁcant rules as
a committee, misclassiﬁes only four samples. Their induced
rules are also more interpretable compared to the functions
that are deﬁned within kernel-based methods. However, like
the C4.5, their rule-based classiﬁer model is susceptible to
the noises in the protein values during diagnoses, and it can-
not encode the causal interactions among important proteins.
Knowledge Discovery from Noisy Data Set
An important purpose in the analysis of biomedical data is to
discover interactions or causal relationships among features.
Not only can the discovered protein interactions be biologi-
cally informative, their dependencies can be effectively ex-
ploited for robust prediction of diseases like ovarian cancer.
Phase 1 - Data Preprocessing
Normalization To ensure comparability across the spec-
tra, the intensity values are normalized according to the pro-
cedure outlined by the Clinical Proteomics Program Data-
bank and described in Sorace & Zhan (2003). The normal-
ization is done over all the 253 examples for all the 15,154
mass-to-charge M/Z identities using the following formula:
NI =
RI −Min
Max−Min (1)
where NI represents the normalized intensity, RI repre-
sents the raw intensity, and Min and Max refer to the mini-
mum and maximum intensity of the pooled examples. After
normalization, the intensity values will be between 0 and 1.
Dimensionality Reduction and Discretization We adopt
entropy-based discretization (Fayyad & Irani 1993) in this
work as it is known to be effective for: (i) ignoring trivial
variations in intensity due to noise, and (ii) sifting through
high-dimensional data to select important features that can
distinguish samples from different classes. The method has
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been successfully used for preprocessing high-dimensional
biomedical data (Li, Liu, & Wong 2003; Tan & Pan 2005).
Entropy-based discretization combines the entropy-based
splitting criterion of the C4.5 decision tree (Quinlan 1993)
with a minimum description length stopping criterion. It re-
cursively determines an optimal cutting point for each fea-
ture dimension that maximizes the separation of the classes.
Features with no cutting points are deemed not as important
and thus can be discarded. In this way, the method effec-
tively reduces the feature dimensions and converts the con-
tinuous mass-to-charge (M/Z) markers into discrete features.
Phase 2 - Learning Bayesian Network from Data
The causal interactions among a set of variables can be mod-
elled in the directed acyclic graphical model of a Bayesian
network (Pearl 1988). The variable dependencies are cap-
tured qualitatively by the network’s structure, i.e., the arcs
linking the variables (nodes), and quantitatively by the table
of conditional probabilities associated with each node. In
this work, we adopt the CaMML program (Wallace & Korb
1999) for supervised Bayesian network learning from data.
CaMML stochastically searches over the entire space of
causal models to ﬁnd the best model that maximizes a Min-
imum Message Length (MML) posterior metric (Korb &
Nicholson 2004). For each real model it visits, it computes
a representative model and counts only on these representa-
tives to overlook the trivial variations. The MML posterior
of each representative is computed as the total MML pos-
terior of its members. This total posterior approximates the
probability that the true model lies within the MML equiv-
alence class of the representative. The best model is hence
the representative model with the highest MML posterior.
The learned Bayesian network is promising for analyz-
ing interacting quantities such as expression data (Friedman
et al. 2000). Firstly, Bayesian networks effectively repre-
sent causal dependencies among multiple interacting pro-
teins. Secondly, they describe local interactions well, as
the value of each node directly depends upon the values of
a relatively small number of neighboring proteins. Finally,
Bayesian networks are probabilistic in nature, and hence are
capable of handling the noise by taking account of the uncer-
tainty in the evidence presented for different network nodes.
Phase 3 - Discovering Erroneous Markers
A set of data is erroneous if it involves markers that carry
some probability of being incorrect in their observed values.
An error rate of e for a marker m implies that observations
on m are wrong e*100% of the time. In practice, we do not
know how many and which of the markers are erroneous, so
our procedure must be ﬂexible enough to discover multiple
erroneous markers, each suffering an unknown rate of error.
As summarized in Algorithm 1, the discovery procedure
takes in an erroneous data set, and a Bayesian network that
concisely represents the data’s joint probability distribution
while ignoring most of the noises in the markers. Predicting
with this model, we identify the top-most erroneous marker
by using the proportion of misclassiﬁed training examples as
an estimate for each marker’s probability of error. Account-
ing for the estimated errors on this top marker by entering it
Algorithm 1 Error Discovery Procedure
Input: Training data (D) containing erroneous records,
Bayesian network (BN ) learned on D, and error threshold (t).
Output: Erroneous markers (M ), and their est. error rates (R).
Step 1: Identify the top erroneous marker mtop.
Set the ﬁrst marker, m1, as mtop.
for each record in D do
Cover-up m1 and predict its value using BN .
Compute Perr(m1) as fraction of D that m1 is misclassiﬁed.
Set top to Perr(m1).
for each remaining marker mi do
for each record in D do
Cover-up mi and predict its value using BN .
Compute Perr(mi) as fraction of D that mi is misclassiﬁed.
if Perr(mi) > top then
Set mtop to mi.
Set top to Perr(mi).
if top ≥ t then
Add mtop to M and add top to R.
else
return M and R as empty sets.
Step 2: Identify the remainder of sets M and R.
while ∃ marker /∈M do
Estimate likelihoods of values in M using R.
Identify the next-most erroneous marker mnext.
if Perr(mnext) ≥ t then
Add mnext to M and update R.
else
Update R; Break.
return the non-empty sets M and R.
as an uncertain (likelihood) evidence, we look for the next-
most erroneous marker, and so on until the estimated error
rate falls below a predeﬁned threshold. In this way, the pro-
cedure discovers the error markers and estimates their error
rates, based on the intuition that the noisiest markers should
also be the markers that are least consistent with the learned
network’s joint distribution. The error threshold serves to ﬁl-
ter out the small degrees of natural randomness in the protein
behaviors. In our experience, a suitable threshold value for
protein spectra analysis is less than 0.1, such that as many of
the possibly erroneous markers can be identiﬁed as possible.
Phase 4 - Predicting under Uncertainties
Predicting using Learned Bayesian Network We predict
the disease category (e.g. cancer, normal) with the learned
Bayesian network by feeding in the collected protein expres-
sion levels, and then allowing the beliefs within the network
to be updated. The category with the highest posterior prob-
ability is the network’s inference, or diagnosis. This process
of prediction using Bayesian network is summarized below:
Step 1: For an unseen sample, present the corresponding
serum expression proﬁle to the learned Bayesian network.
Step 2: Let the network update the posterior probabilities
of all its nodes based on the evidence. We use the fastest
known algorithm for exact general probabilistic inference
in a compiled Bayesian network, called message passing
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in a join (or “junction”) tree of cliques (Neapolitan 1990).
Step 3: Predict, for the given sample, the disease category
(cancer, non-cancer) with the largest posterior probability.
Empirically, we observe that this Bayesian network infer-
ence mechanism is highly efﬁcient. In the experiments, each
prediction took less than 0.1 seconds on a PC.
Likelihoods Estimation We would expect the new, or the
unseen, samples to be noisy as well, with noise character-
istics similar to samples in the training data. In the normal
prediction scenario, where we are not aware of possible er-
rors in the marker values, we enter each reading given in
the test sample as a speciﬁc evidence. However, when there
are errors in the readings of the marker, entering these erro-
neous readings as speciﬁc ﬁndings would very likely result
in wrong predictions. Fortunately, the Bayesian network al-
lows us to specify such potentially erroneous evidence as
likelihoods to reﬂect our uncertainty regarding the evidence.
We should take into consideration the prior probability for
each possible value of an erroneous marker in estimating its
likelihoods (Korb & Nicholson 2004). The prior probability
for the value vm of a marker m is the proportion of exam-
ples within the training data for which vm is present. For in-
stance, the prior probability for each of the possible values of
marker “MZ261.88643” (hereafter referred as MZ261) can
easily be computed from the training data, giving us an ar-
ray of priors P (vm), where vm ∈ {0, 1, 2, 3}. Now, let the
observation on MZ261 be O. The likelihoods for O are then
given by {prob (O | MZ261=“0”), prob (O | MZ261=“1”),
prob (O | MZ261=“2”), prob (O | MZ261=“3”)}.
For the example where we observe the MZ261 as “3”,
suppose we are aware that this observation carries an esti-
mated error rate of e. This means that each observation for
MZ261 might be wrong e∗100% of the time. This error rate
for the erroneous marker could be estimated using the train-
ing error rate discovered by our error discovery procedure.
The likelihoods for O:{MZ261=“3”} would then be com-
puted as {P (0) ∗ e ∗P (3), P (1) ∗ e ∗P (3), P (2) ∗ e ∗P (3),
P (3) ∗ (1.0 − e)}, where P (v) denotes the prior of v. This
is because the probability of observing the MZ261 as “3”
when it is actually “0”, “1” or “2” is simply the probability
of one of these three values being present in the sample but
we wrongly record the marker as “3”. We can generalize the
estimation of likelihoods from the error rate e as follows:
Likelihood of the observed v = P (v) ∗ (1.0− e), and
Likelihood of any other value v′ = P (v′) ∗ e ∗ P (v).
Entering an error rate of zero for a marker is equivalent to
entering a speciﬁc ﬁnding, so the above likelihood formula-
tion is appropriate even when the reading is made with a full
certainty. By properly accounting for these conﬁdence in the
erroneous marker values, our automatic error discovery and
likelihoods estimation procedure enables the learnt network
to overcome noise and predict accurately on unseen data.
Experimental Validation
The ovarian data set contains 162 cancer and 91 normal sam-
ples. Similar to Sorace & Zhan (2003), we randomly select
81 cancer patients and 45 controls for training, leaving the
Table 1: The top 10 proteins selected in decreasing order of
information gain.
Protein (M/Z) Information Gain Cutting Points
MZ261.88643 0.8190 0.3771,0.4011,0.4388
MZ262.18857 0.7627 0.4317, 0.5107
MZ245.24466 0.7381 0.4508
MZ244.95245 0.7381 0.4350
MZ245.8296 0.7219 0.3908
MZ245.53704 0.7219 0.5052
MZ244.66041 0.7202 0.2098, 0.3608
MZ246.12233 0.6903 0.3478
MZ435.07512 0.6693 0.3647
MZ434.29682 0.6650 0.4461, 0.5249
MZ245.24466
MZ244.95245 MZ245.8296Category
MZ261.88643 MZ435.07512 MZ244.66041 MZ245.53704
MZ246.12233MZ434.29682MZ262.18857
Figure 1: Bayesian network learned from the training data.
rest for testing. In this section, we ﬁrst present the discretiza-
tion results on which proteins are selected for further analy-
sis. We then present our important results, on the discovered
causal proteins interactions in the learned Bayesian network,
and the approach’s efﬁcacy at diagnosing for ovarian cancer.
Using the entropy-based feature selection and discretiza-
tion method, only 4796 of the 15,154M/Z values in the train-
ing data are partitioned into two to four intervals each, while
there are no cutting points for the other attributes. This indi-
cates that only 4796/15,154 = 31.6% of the features can be
considered as discriminatory and the rest are negligible. De-
riving this much smaller set of informative proteins helps us
to more efﬁciently identify the important causal interactions.
Next, we examine all the 4796 selected features and sort
them in decreasing order of information gain, a formal mea-
sure that reﬂects the reduction in entropy that is obtained by
splitting the training data on individual proteins. Perfect pre-
diction on the training data is readily achieved using the top
10, top 15 and top 20 proteins, but based on just the top ﬁve
proteins, two of the 45 control samples in the training set are
misclassiﬁed. Therefore, we proceed to learn the causal in-
teractions among all the top 10 proteins as listed in Table 1.
Figure 1 presents the Bayesian network that has been au-
tomatically learned from the training data based on the top
10 proteins with the highest information gains. The Markov
blanket for the target node of Category has been demarcated,
and composes of the Category’s parents, its children, and the
parents of its children. In any Bayesian network, theMarkov
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Table 2: The discovered error information on the proteins.
Proteins are listed in decreasing order of est. error rate.
Name of the Protein (M/Z) The Estimated Error Rate
MZ244.66041 0.2063
MZ434.29682 0.1429
MZ261.88643 0.0952
MZ262.18857 0.0952
MZ435.07512 0.0476
MZ245.24466 0.0079
MZ244.95245 0.0079
MZ246.12233 0.0079
MZ245.53704 0.0
MZ245.8296 0.0
blanket of a node shields off the rest of the network from the
node, and is all that is needed to predict the behavior of that
node. Since each M/Z feature describes a serum protein, it
should interest biologists that the disease’s category can be
fully predicted by just the highlighted set of proteins.
It is interesting to note that this small set of proteins within
the Markov blanket of our learned causal model in fact over-
laps with the set of proteins that Sorace & Zhan (2003) have
identiﬁed using stepwise discriminant analysis. Speciﬁcally,
both “MZ261.88643” and “MZ435.07512” are found to pos-
sess an exceptionally strong diagnostic power in both exper-
iments. Based on this ﬁnding, there is further reason to be-
lieve that these proteins are closely related to ovarian cancer.
Wemake use of this network for investigating whether our
proposed error discovery and likelihoods estimation proce-
dure can indeed contribute to more robust predictions. First,
we employ this learned model to predict on the set of masked
test data without applying our error-handling procedure. It
is found that this learned model is reasonably accurate, mis-
classifying only one of the 81 cancer and one of the 46 nor-
mal samples. This gives a sensitivity (cancer-class recall) of
98.77%, a speciﬁcity (normal-class recall) of 97.83%, and a
positive predictive value (cancer-class precision) of 98.77%.
We investigate whether the misclassiﬁcations can be cor-
rected using our proposed error-handling procedure. First,
we apply our proposed error discovery procedure of Algo-
rithm 1 to identify the erroneous proteins and also obtain es-
timates of their error rates. Using a minimum error threshold
of zero, the algorithm automatically discovers that eight out
of the ten proteins have some evidence of errors (Table 2),
although only the ﬁrst few most-erroneous proteins have an
estimated error rate that is above 0.10. This information on
the individual protein’s error rate encompasses the important
discovered knowledge about each measurement’s reliability.
Next, based on these estimated error rates, we compute
the likelihoods estimates for each protein when entering its
observed values into the Bayesian network during testing.
Using the learned model presented in Figure 1, we apply our
procedure to the same test samples. This produces a perfect
classiﬁcation for all 127 unseen samples. Details of the cor-
rections in the two samples that are misclassiﬁed earlier are
presented in Table 3. We can see that the beliefs of proteins
Table 3: Samples that are correctly classiﬁed only after ap-
plying our error discovery and likelihoods estimation proce-
dure. The proteins are in the same order as shown in Table 1.
Protein values before Class Label Prediction (Prob.)
error compensation
2, 0, 1, 1, 0, 0, 2, 0, 1, 2 Cancer Normal (0.600)
0, 0, 1, 1, 1, 0, 1, 1, 0, 0 Normal Cancer (0.564)
Protein values after Class Label Prediction (Prob.)
error compensation
2, 0, 1, 1, 0, 0, 0, 0, 1, 2 Cancer Cancer (0.832)
0, 0, 1, 1, 1, 0, 1, 1, 0, 0 Normal Normal (0.619)
within the Bayesian network have been updated, to the ex-
tent that the most-probable protein values may differ from
their ﬁndings. This results in the correct predictions, each of
which has a higher probability, or a higher level of certainty.
We repeat the experiment for ﬁve rounds of ten-fold strat-
iﬁed validations. In each round, the samples are randomly
divided into ten equal portions. For each fold, one portion is
left out for testing, while we train on the remaining samples.
By coupling entropy-based discretization with Bayesian net-
work learning as we have proposed, the predictive accuracy,
i.e., the average percentage of test samples that are correctly
classiﬁed within the ﬁfty splits, is 96.46%. We note that this
already corresponds to just a single misclassiﬁcation on av-
erage. With error discovery and likelihoods estimation, the
accuracy improves further to 96.70%, with more of the splits
producing perfect diagnostic sensitivity and speciﬁcity.
Apart from predictive accuracy, the direct interpretabil-
ity of the discovered model of causal protein interactions is
an important advantage of our proposed approach. For ex-
ample, besides the information on the Markov blanket, we
can also begin to understand the effects of errors in different
proteins upon the diagnosis. With reference to Figure 1, the
protein “MZ244.66041” is directly connected to the “Cate-
gory” node that predicts the disease category, as well as to
another protein “MZ245.8296”. From Table 2, we observe
that these are respectively the most and least erroneous pro-
teins. As such, our likelihoods estimation procedure would
have entered the value of “MZ244.66041” with much lower
certainty than “MZ245.8296”, allowing the latter to correct
the former. True enough, we see from the ﬁrst sample of Ta-
ble 3 that a key reason for the correct prediction after error
compensation is the correction in value of “MZ244.66041”.
Another important advantage of learning causal models
is that explanations can be generated automatically from the
learned Bayesian networks to aid in interpretation. In a com-
panion paper (Yap, Tan, & Pang 2007), we have presented a
novel approach that explains the Bayesian network’s diagno-
sis using a minimal set of features, by exploiting the fact that
the conclusions of the diagnostic node can be completely ex-
plained with just the nodes in its Markov blanket. Empirical
evaluations based on multiple real-world data sets show that,
by focusing on the nodes within the Markov blankets, we are
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able to generate high-quality explanations for the probabilis-
tic inferences in learned Bayesian networks. The following
example shows an explanation for the ﬁrst sample in Table 3.
This automatically-generated explanation clearly highlights
the compensation for “MZ244.66041” during the diagnosis.
BN predicts Cancer with probability 0.832 because
MZ245.24466 is 1 with probability 0.968,
MZ245.8296 is 0 with probability 1.0,
MZ244.66041 is 0 with probability 0.600,
MZ435.07512 is 1 with probability 0.993, and
MZ261.88643 is 2 with probability 0.616.
BN corrects MZ244.66041 from 2 to 0 because
Given MZ245.8296 is 0,
MZ244.66041 is 2 with probability 0.266, and
MZ244.66041 is 0 with probability 0.600.
Conclusion
We have presented a systematic mechanism for learning, ex-
tracting, and exploiting the knowledge of the causal interac-
tions contained in noisy biological data for cancer detection.
Based upon the strong statistical foundation of the Bayesian
network, experimental results on a high-dimensional ovarian
cancer data from the Clinical Proteomics Program Databank
show that the proposed knowledge discovery approach con-
tributes signiﬁcantly to more robust predictive performance.
Even with just ten proteins, the empirical results show that
the normal and cancer sera could be perfectly distinguished.
In addition to predictive accuracy, the ability to generate
interpretable knowledge is the key strength of our approach.
In assigning each unseen sample to its most-probable cate-
gory, the Bayesian network uses its probabilities as the basis
for its conﬁdence. Most importantly, the Bayesian network
that is learned from data can be readily veriﬁed by, and inte-
grated with, the prior knowledge from medical practitioners,
biologists, and the other experts from different related ﬁelds.
Having a systematic approach to discover and to exploit
causal interactions, our next step would be to work with the
experts to interpret and validate the knowledge discovered
by the system. Ultimately, we aim to ﬁnd a diagnostic model
for diseases like the ovarian cancer that not only is extremely
sensitive and speciﬁc, but also describes biologically plausi-
ble interactions, as this is the only way for knowledge found
from small data sets to generalize. Hopefully, this could lead
to a better screening tool for women who are at high risk of
ovarian cancer. This would form the core of our future work.
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